ISRCTN39855523已完成不适用
Portal vein embolization with n-butyl-cyanoacrylate through an ipsilateral approach before major hepatectomy: single center retrospective analysis of 50 consecutive patients
ational Cancer Institute of Brazil INCA0 个研究点目标入组 50 人开始时间: 2017年3月13日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 性别
- All
入选标准
- •1. Patients with primary and secondary liver cancer treatable by hepatectomy
- •2. Proportion of FLR volume to the total functional liver volume (TFLV) less than 25% or less than 40% in patients with previous chemotherapy or hepatic cirrhosis.
- •3. Aged between five to 75 years old
排除标准
- •1. Extensive ipsilateral tumor precluding safe access to the portal vein
- •2. Unmanageable coagulopathy
- •3. Extensive extra-hepatic disease
- •4. Liver abscess or infection
研究者
相似试验
招募中
不适用
Endovascular treatment using N-Butyl Cyanoacrylate (NBCA) liquid adhesive for arteriovenous malformations, dural arteriovenous fistulas and brain tumorsarteriovenous malformations, dural arteriovenous fistulas and brain tumorsJPRN-UMIN000020435chiyama Naoyuki Mohri Masanao Misaki Kouichi20
已完成
不适用
Transcatheter Catheterl Embolization with N-butyl-2-cyanoacrylateThe patient with the situation that transcatheter embolization has to be performed using NBCAJPRN-UMIN000022611Kyoto University30
已完成
不适用
Use of N-Butyl Cyanoacrylate in Transarterial Emergency EmbolizationHaemostasis EmbolisationNCT06301919Centre Hospitalier Universitaire de Saint Etienne122
尚未招募
2 期
Balloon occluded transarterial chemoembolization using miriplatin in HCC: A Multicenter, Clinical Phase II studyHepatocellular carcinomaJPRN-UMIN000029504The Japanese Society for Transcatheter Hepatic Arterial Embolization52
招募中
2 期
RAIB-TACE for Hepatocellular Carcinoma refractory or intolerant to Atezolizumab plus BevacizumabHepatocellular Carcinoma, atezolizumab, bevacizumab, TACED006528Hepatocellular CarcinomaJPRN-jRCTs031210114Hasegawa Naoyuki19